Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Liver Neoplasms 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Acrocephalosyndactylia 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Neoplasms 1Carcinoma, Transitional Cell 1Bile Duct Neoplasms 1

Interventions

Sorafenib 23Bevacizumab 11Radiosurgery 6Capecitabine 6Radiofrequency Ablation 5Oxaliplatin 5Fluorouracil 5Doxorubicin 5pembrolizumab 4Sunitinib 4Erlotinib Hydrochloride 4Cisplatin 4Ramucirumab 3Radiotherapy 3Nivolumab 3Leucovorin 3Carboplatin 3tremelimumab 2spartalizumab 2perflutren 2derazantinib 2carotuximab 2Mitomycin 2Magnetic Resonance Spectroscopy 2Magnetic Resonance Imaging 2Ipilimumab 2Immunohistochemistry 2Gemcitabine 2Folfox protocol 2Fluorodeoxyglucose F18 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Liver Neoplasms × derazantinib × Clear all
NCT03230318 2023-12-19

FIDES-01

Basilea Pharmaceutica

Phase 2 Completed
148 enrolled 15 charts
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Liver Neoplasms, Cholangiocarcinoma

NCT01752920 2023-06-05

Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

Basilea Pharmaceutica

Phase 1/2 Completed
119 enrolled 15 charts
Gastrointestinal

Biliary Tract Neoplasms, Liver Neoplasms, Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡